Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
IF – 2.1 (5-Year IF – 2.0), JCI (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.3)
Q1 in SJR 2024, SJR score – 0.598
IC – 171.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 5, September-October, p. 871–878

doi: 10.17219/acem/61953

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Clarithromycin Decreases IL-6 Concentration in Serum and BAL Fluid in Patients with Cryptogenic Organizing Pneumonia

Elżbieta Radzikowska1,A,B,C,D,E,F, Adriana Roży2,B,C,D,E,F, Paulina Jagus2,B,C,D,E,F, Małgorzata Polubiec-Kownacka3,B,D,E,F, Elżbieta Wiatr1,C,E,F, Joanna Chorostowska-Wynimko2,C,E,F, Kazimierz Roszkowski-Śliż1,C,E,F

1 Third Department of Lung Disease, National Tuberculosis and Lung Disease Research Institute, Warszawa, Poland

2 Laboratory of Molecular Diagnostics and Immunology, National Tuberculosis and Lung Disease Research Institute, Warszawa, Poland

3 Thoracic Surgery Department, National Tuberculosis and Lung Disease Research Institute, Warszawa, Poland

Abstract

Background. Inflammatory cytokines are involved in the development of cryptogenic organizing pneumonia (COP). It has been shown that macrolides inhibit cytokine production in the alveolar macrophages of COP patients.
Objectives. The aim of the study was to assess the concentrations of interleukin 1β (IL-1β), IL-6, IL-8 and transforming growth factor β (TGF-β) in serum and in bronchoalveolar lavage fluid (BAL-f) in COP patients treated with clarithromycin (CAM).
Material and Methods. The study involved 26 patients (18 women and 8 men, mean age 56.46 ± 8.83 years) with biopsy-proven COP. After being treated with CAM, a complete recovery was achieved in 22 patients, while four patients did not respond to the treatment. The ELISA method was used to measure the serum and BAL-f concentrations of IL-1β, IL-6, IL-8 and TGF-β.
Results. Before treatment, the serum IL-1β1, IL-6, IL-8 and TGF-β1 concentrations were similar in responders and non-responders. Significant decreases in serum concentrations of IL-6 (8.98 ± 13.26 pg/mL vs. 3.1 ± 6.95 pg/mL; p = 0.005), IL-8 (20.14 ± 25.72 pg/mL vs. 10.14 ± 6.8 pg/mL; p = 0.007) and TGF-β1 (37.89 ± 12.49 ng/mL vs. 26.49 ± 12.45 ng/mL; p = 0.001) were found after treatment, as well as a significant decrease in the BAL-f concentration of IL-6 (30.56 ± 56.78 pg/mL vs. 4.53 ± 5.84 pg/mL; p = 0.036). Clarithromycin treatment resulted in a significantly lower mean value of serum IL-6 responders than non-responders.
Conclusion. In COP patients, response to clarithromycin treatment was associated with decreases in serum concentrations of IL-6, IL-8 and TGF-β, and of rations, and of the BAL-f concentration of IL-6.

Key words

interleukin-1β, transforming growth factor-β, organizing pneumonia, interleukin-8, bronchoalveolar lavage

References (30)

  1. Cotin V, Cordier JF: Cryptogenic organizing pneumonia. Semin Respir Crit Care Med 2012, 33, 462–475.
  2. Travis WD, Costabel U, Hansell DM, Lynch DA, Nicholson AG, Ryerson ChJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, InoueY, Johkoh T, Soon Kim D, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D, ATS/ERS Committee on Idiopathic Interstitial Pneumonias: An official American Thoracic Society/European Respiratory Society statement: Update of international multidisciplinary classification of idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013, 188, 733–748.
  3. Drakopanagiotakis F, Paschalaki K, Abu-Hijleh M: Cryptogenic organizing pneumonia. Clinical presentation, radiographic findings, treatment response and prognosis. Chest 2011, 139, 893–900.
  4. Poletti V, Cazzato S, Minicuci N, Zompatori M, Burzi M, Schiattone ML: The diagnostic value of bronchoalveolar lavage and transbronchial biopsy in cryptogenic organizing pneumonia. Eur Respir J 1996, 9, 2513–2525.
  5. Florani S, Ratta L, Bulgheroni A, Cascina A, Paschetto E, Cervio G, Luinetti O, Fietta AM, Meloni F: Cytokine profile of bronchoalveolar lavage in BOOP and UIP. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19, 47–53.
  6. Cai M, Bonella F, He X, Sixt SU, Sarria R, Guzman J, Costabel U: CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. Respir Med 2013, 107, 1444–1452.
  7. Cai M, Bonella F, Dai H, Sarria R, Guzman J, Costabel U: Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. Immunobiology 2013, 218, 930–937.
  8. Carre C, King TE, Mortensen R, Riches DWH: Cryptogenic organizing pneumonia: increased expression of interleukin 8 and fibronectin genes by alveolar macrophages. Am Rev Respir Cell Mol Biol 1994, 10, 100–105.
  9. Martinez JAB, King TE, Brown K. Jennings CA, Borish L, Mortenson RL, Khan TZ, Bost TW, Riches DW: Increased expression of the interleukin-10 gene by alveolar macrophages in interstitial lung disease. Am J Physiol 1997, 273, 676–683.
  10. Matsuno O, Okubo F, Masutomo K, Yoshida F, Okubo T, Miyazaki E, Kumamoto T: Elevated concentrations of soluble IL-2 receptor in both broncholveolar lavage fluid and serum in patients with BOOP. Tohoku J Exp Med 2003, 201, 61–65.
  11. Ye Q, Dai H, Sarria R, Guzman J, Costabel U: Increased expression of tumor necrosis factor receptors in cryptogenic organizing pneumonia. Respir Med 2011, 105, 292–297.
  12. Choi KH, Lee HB, Jeong MY, Jeong MY, Rhee YK, Chung MJ, Kwak YG, Lee YC: The role of matrix metalloproteinase9 and tissue inhibitor of metaloproteinase-1 in cryptogenic organizing pneumonia. Chest 2002, 121, 1478–1485.
  13. El-Zammar O, Rosenbamum P, Katzenstein AL: Proliferate activity in fibrosing lung diseases: A comparative study of Ki-67 immunoreactivity in diffuse alveolar damage, bronchiolitis organizing pneumonia, and usual interstitial pneumonia. Human Path 2009, 40, 1182–1188.
  14. Lappi-Blanco E, Soni Y, Paako P: Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. Lung 1999, 177, 367–376.
  15. Majeski E, Harley RA, Bellum SC, London SD, London L: Differential role for T cells in the development of fibrotic lesions associated with reovirus 1/l-induced bronchiolitis obliterans organizing pneumonia versus acute respiratory distress syndrome. Am J Respir Cell Mol Biol 2003, 28, 208–217.
  16. Amayasu H, Yoshida S, Ebana S, Yamamoto Y, Nishikawa T, Shoji T, Nakagawa H, Hasegawa H, Nakabayashi M, Ishizaki Y: Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000, 84, 594–598.
  17. Corris PA, Ryan VA, Small T, Lordan J, Fisher AJ, Meachery G, Johnson G, Ward C: A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax 2015, 70, 442–450.
  18. Haghi M, Saadat A, Zhu B, Colombo G, King G, Young PM, Traini D: Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler. Pharm Res 2015, 32, 2144–2153.
  19. Southern KW, Barker PM, Solis-Moya A, Patel L: Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012, 11, CD002203.
  20. Ding QL, Lv D, Wang BJ, Zhang QL, Yu YM, Sun SF, Chen ZB, Ma HY, Deng ZC: Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review. Exp Ther Med 2015, 9, 829–834.
  21. Pathak V, Kuhn JM, Durham C, Funkhouser WK, Henke DC: Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. Ann Am Thorac Soc 2014, 11, 87–91.
  22. Radzikowska E, Wiatr E, Gawryluk D, Langfort R, Bestry I, Chabowski M, Roszkowski K: Organizing pneumonia – clarithromycin treatment. Pneumonol Alergol Pol 2008, 76, 334–339.
  23. Kanoh S, Rubin BK: Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010, 23, 590–615.
  24. Asano T, Ogushi F, Tani K, Tamiya H, Nishioka Y, Sone S: Increased macrophage inflammatory protein-1 alpha and -1beta in BAL fluid of bronchiolitis obliterans organizing pneumonia. Respirology 2003, 8, 461–466.
  25. Shinkai M, Henke MO, Rubin BK: Macrolide antibiotics as immunomodulatory medications: Proposed mechanism of action. Pharmacol Ther 2008, 117, 393–405.
  26. Ichiyama T, Nishikawa M, Yoshitomi T, Hasegawa S, Matsubara T, Hayashi T, Furukawa S: Clarithromycin inhibits NF-kappa B activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001, 45, 44–47.
  27. Ribeiro CM, Hurd H, Wu Y, Martino ME, Jones L, Brighton B, Boucher RC, O’Neal WK: Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS One 2009, 4, e5806.
  28. Streetz KL, Wüdstefeld T, Klein C, Manns MP, Trautwein C: Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) 2001, 47, 661–673.
  29. Rubin A: Interleukin-6 and lung inflammation: Evidence for a causative role in inducing respiratory system resistance increments. Inflamm Allergy Drug Targets 2013, 12, 315–321.
  30. Lazor R, Vandevenne A, Pelletier A, Leclerc P, Court-Fortune I, Cordier JF: Cryptogenic organizing pneumonia. Characteristics of relapses in series of 48 patients. Am J Respir Crit Care Med 2000, 162, 571–577.
© Wroclaw Medical University